1-Tert-butyl-4,4-diphenylpiperidin-1-ium;chloride | 63661-61-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-Tert-butyl-4,4-diphenylpiperidin-1-ium;chloride
• CAS: 63661-61-0
• 化学式: C21H28ClN
• 分子量: 329.9
• InChiKey: USUUKNCFNKZGEY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.29
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  3.2
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• "Methods for treatment of Parkinson's disease"
  申请人：Newron Pharmaceuticals S.p.A.

  公开号：EP2070526A1

  公开（公告）日：2009-06-17

  New uses of safinamide, safinamide derivatives and MAO-B inhibitors in novel types of treatment for Parkinson's Disease are described. More specifically, the invention relates to methods for treating Parkinson's Disease through the administration of safinamide, a safinamide derivative, or a MAO-B inhibitor, in combination with other Parkinson's Disease agents or treatments, such as levodopa/PDI or dopamine agonists.

  本发明描述了沙芬胺、沙芬胺衍生物和 MAO-B 抑制剂在新型帕金森病治疗中的新用途。更具体地说，本发明涉及通过服用沙芬胺、沙芬胺衍生物或 MAO-B 抑制剂，结合其他帕金森病药物或疗法（如左旋多巴/PDI 或多巴胺激动剂）治疗帕金森病的方法。
• Kinase inhibitors for treating cancers
  申请人：Agennix USA Inc.

  公开号：EP2298292A2

  公开（公告）日：2011-03-23

  The invention pertains to inhibitors of various kinases (e. g. S/T kinases; Tyr kinases etc.) which inhibitors are previously known as cyclin dependent kinase inhibitors (CDKs). As described therein, the inhibitors of this invention are capable of inhibiting various wild-type and mutant form kinases, including drug resistant forms of mutant kinases. Thus the subject kinase inhibitors are useful in treating a wide range of diseases / conditions associated with abnormal functions / excessive activities of the target kinases, including mutant kinases. The invention further provides methods for treating cancers, tumors and patients which are resistant or refractrory to other therapeutic agents. Pharmaceutical compositions and packaged pharmaceuticals which instructions of these inhibitors, and methods of using these inhibitors are also provided.

  本发明涉及各种激酶（如 S/T 激酶、Tyr 激酶等）的抑制剂，这些抑制剂以前被称为细胞周期蛋白依赖性激酶抑制剂（CDK）。如其中所述，本发明的抑制剂能够抑制各种野生型和突变型激酶，包括突变型激酶的耐药形式。因此，本发明的激酶抑制剂可用于治疗与靶激酶（包括突变型激酶）的异常功能/过度活性相关的多种疾病/病症。本发明进一步提供了治疗对其他治疗剂耐药或难治的癌症、肿瘤和患者的方法。本发明还提供了说明这些抑制剂的药物组合物和包装药品，以及使用这些抑制剂的方法。
• Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
  申请人：The Scripps Research Institute

  公开号：US10660899B2

  公开（公告）日：2020-05-26

  The present invention provides methods of inducing differentiation of oligodendrocyte progenitor cells to a mature myelinating cell fate with a neurotransmitter receptor modulating agent. The present invention also provides methods of stimulating increased myelination in a subject in need thereof by administering said neurotransmitter receptor modulating agent. Methods of treating a subject having a demyelinating disease using a neurotransmitter receptor modulating agent are also provided.

  本发明提供了用神经递质受体调节剂诱导少突胶质祖细胞向成熟髓鞘细胞命运分化的方法。本发明还提供了通过施用所述神经递质受体调节剂刺激有需要的受试者增加髓鞘化的方法。本发明还提供了使用神经递质受体调节剂治疗脱髓鞘疾病的方法。
• DIRECTED DIFFERENTIATION OF OLIGODENDROCYTE PRECURSOR CELLS TO A MYELINATING CELL FATE
  申请人：The Scripps Research Institute

  公开号：EP2675893A1

  公开（公告）日：2013-12-25
• US7790905B2
  申请人：——

  公开号：US7790905B2

  公开（公告）日：2010-09-07